Go Pro
NASDAQ:IMCC

IM Cannabis Q2 2026 Earnings Report

IM Cannabis logo
$0.10 0.00 (-0.10%)
Closing price 08/18/2026 04:00 PM Eastern
Extended Trading
$0.10 -0.01 (-5.24%)
As of 08/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis EPS Results

Actual EPS
-$0.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

IM Cannabis Revenue Results

Actual Revenue
$5.34 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IM Cannabis Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
9:00AM ET

Earnings Documents

IM Cannabis Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
IM Cannabis Provides Corporate Update
See More IM Cannabis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email.

About IM Cannabis

IM Cannabis (NASDAQ:IMCC) Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners.

Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.

View IM Cannabis Profile